Thursday, 8 November 2007

Fund Manager Says The Market “Missed The Point”

Neptune Technologies & Bioressources (NTB – TSX V / NEPT – NASDAQ)

Northern Rivers Fund Manager Hugh Cleland was pointed in his Wednesday, November 7th appearance on BNNtv that the market missed the significance of Dr. Steve Nissen joining Neptune’s advisory board as announced on October 15th.

Mr.Cleland’s comments came as a result of a phone-in question. He said he was surprised by the lack of public acknowledgement of the importance of the announcement, including from analysts covering Neptune and had expected the stock would rise to the $6 level just on the news.

Steven E. Nissen, M.D., MACC, is the Chairman of the Cleveland Clinic Department of Cardiovascular Medicine, and Immediate Past President, American College of Cardiology, Washington, DC. He previously served as the Medical Director of the Clinic’s Cardiovascular Coordinating Center.

He was the key individual that took Pfizer to task for its clinical trials on torcetrapib, a drug that at one time looked like to could be the holy grail in the fight against cholesterol and cardiovascular diseases.

Dr. Nissen was named by TIME Magazine in May of this year as “one of the 100 Most Influential People in the world” coming in at number 72. Click here to read the story.

To listen to Mr. Cleland’s comments go to Small Caps, 11:30 segment on Wednesday and forward to the 16:50 mark.